cometadata/datacite-rtg-text-other-reclassification-records huggingface dataset:
Number needed to treat (NNT) with pembrolizumab as an adjuvant therapy in resected patients with high-risk stage II (IIB and IIC) melanoma and its application to cost of preventing an event (COPE) in Mexico
Creators: name: Wurcel, Victoria
name: Rojas, Mónica Rojas
name: Urrego-Reyes, Juan
name: Rivera, Daniela Medrano
name: Acevedo, Roberto
name: Jiang, Ruixuan
name: Jiang, Shan
name: Zhang, Shujing
name: Caparros, Alfredo
name: Krepler, Clemens
name: Fukunaga-Kalabis, Mizuho
name: Younan, Nadine D.
name: Alexander, Deepak
name: Hughes, Robert
name: Weston, Georgie
Publisher: name: Taylor & Francis
Year: 2025
Subjects: Medicine
Biological Sciences not elsewhere classified
Developmental Biology
Cancer

description: Melanoma, responsible for most skin cancer deaths globally, has mortality rates expected to double by 2040. Pembrolizumab is a highly selective antibody approved for melanoma treatment and other cancers. Despite new treatments for melanoma, high treatment costs and long approval times limit patient access to new therapies. To support decision-making regarding metastatic melanoma therapies, a model was developed to calculate the number needed to treat (NNT) and the cost of preventing an event (COPE) using KEYNOTE-716 (NCT03553836) data. A cost-per-responder model comparing the clinical and economic impacts of pembrolizumab versus best supportive care (BSC) was developed considering a 52.8-month follow-up for recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with resected high-risk melanoma. KEYNOTE-716 RFS and DMFS survival curves were used to calculate restricted mean survival time (RMST). The RMST was used to calculate NNT (NNTRMST). The NNTRMST calculates the NNT to result in a difference in mean survival time for a death or an event. NNTRMST is subsequently used to quantify COPE outcomes. NNT for RFS was 5.3, reflecting the number of patients needed to treat to gain the additional difference observed in the mean RFS for resected high-risk type II (IIB and IIC) melanoma patients treated with pembrolizumab. For DMFS, the NNTRMST was 7.8. The estimated COPE to prevent an RFS or DMFS event was Mexican Peso (Mex $) 9,554,593 (2024) and Mex $13,961,427, respectively. NNT values for RFS and DMFS data were both lower than the published average NNT value for current melanoma therapies. This demonstrated that fewer additional patients need to be treated in order to avoid a recurrence or a distant metastases event, compared to currently available melanoma therapies. The NNT and COPE highlight the clinical and economic impact of introducing pembrolizumab therapy for the treatment of patients in resected high-risk stage II melanoma.
Guía técnica para potenciar la calidad de las revistas científicas universitarias del Ecuador
Creators: name: Ernesto Paz Enrique, Luis
name: Estrada Jiménez, Lidia Esther
name: Jalil Vélez, Nadya Judafeet
Publisher: name: Humanities Commons
Year: 2020
Subjects: subject: Periodicals

description: Las revistas científicas universitarias se caracterizan por su calidad traducida en posicionamiento, visibilidad e impacto. La nación del Ecuador presenta solo tres revistas científicas de prestigio. Se planteó como objetivo del estudio diseñar una guía técnica para potenciar la calidad de las revistas científicas universitarias del Ecuador. La guía responde a una necesidad social, a la visibilización del conocimiento como parte de la responsabilidad social de la universidad. Se emplearon métodos en los niveles teórico y empírico. Se exponen diversos aspectos que influyen en la calidad de las publicaciones científicas. Se diseña una guía técnica a través de directrices que potenciará la elevación de las publicaciones científicas universitarias del Ecuador en un período no mayor de cinco años.
Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States
Creators: name: Mahmoudjafari, Zahra
name: Li, Jia
name: Bercaw, Eric
name: Parise, Helene
name: Bognar, Katalin
name: Wang, Si-Tien
name: Masaquel, Anthony
Publisher: name: Taylor & Francis
Year: 2025
Subjects: subject: Medicine
subject: Pharmacology
subject: Biotechnology
subject: Cancer
subject: Science Policy
subject: Hematology
subject: Infectious Diseases
subject: FOS: Health sciences
subject: Plant Biology
subject: FOS: Biological sciences

description: Glofitamab is a T-cell engaging bispecific monoclonal antibody that was granted accelerated approval from the United States Food and Drug Administration for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after ≥2 lines of systemic therapy (3L+). A budget impact model was developed fora hypothetical blended commercial/Medicare health plan with 1,000,000 members. Comparators were axicabtagene ciloleucel (Axi-cel), lisocabtagene maraleucel (Liso-cel), tisagenlecleucel (Tisa-cel), loncastuximab tesirine, polatuzumab vedotin + bendamustine + rituximab, rituximab + gemcitabine + oxaliplatin, tafasitamab + lenalidomide, and epcoritamab (Epcor). Total costs included those for drugs, wastage, administration, grade ≥3 adverse reactions and all-grade cytokine release syndrome) and routine care. Market shares were based on internal projections and expert opinions. Total and per-member per-month (PMPM) net budget impacts over 3 years were calculated. Approximately nine patients were projected to be eligible for 3L + DLBCL treatment in a health plan of 1,000,000 members. The introduction of glofitamab as a treatment option resulted in estimated total and PMPM cost savings of $728,697 and –$0.0202, respectively, over 3 years. Costs were reduced across all cost categories but particularly in drug costs. Among the newer therapies, total 3-year cost per treated patient was lowest for glofitamab: $226,658 versus Tisa-cel = $564,113; Axi-cel = $540,002; Liso-cel = $516,272; and Epcor = $335,293. Across all sensitivity analyses, the inclusion of glofitamab had minimal PMPM budget impact, ranging from –$0.0256 to –$0.0108. With the lowest 3-year total cost per treated patient among the newer therapies, glofitamab being an available option in the 3L + DLBCL market is estimated to save a hypothetical 1,000,000-member health plan $728,697 in cumulative total costs and $0.0202 in PMPM costs over 3 years. Glofitamab is a new treatment for a common type of blood cancer that does not respond to at least two other treatments. This analysis estimated the change in a health plan’s spending over a 3-year period if it covered and used glofitamab rather than epcoritamab or other options and found that the plan’s 3-year spending decreased by $0.02 per plan member per month in overall costs.
Healthcare resource utilization and costs among treatment-naïve people with HIV in state Medicaids: analysis of multi-tablet vs. single-tablet antiretroviral regimen initiators with and without concurrent mental health disorders
Creators: name: Chen, M.
name: Christoph, M.J
name: Park, S.
name: Turkistani, F.
name: Weinberg, A.R
name: Trom, C.
name: Zachry, W.
name: Gruber, J.
name: Mordi, U.
name: Rajagopalan, K.
Publisher: name: Taylor & Francis
Year: 2024
Subjects: Medicine
Cancer
Science Policy
Virology

description: Research is needed to understand the impact of mental health disorders (MHD) on healthcare resource utilization (HCRU) and costs among people with human immunodeficiency virus (PWH). Examine the HCRU and cost burden among treatment-naïve PWH with and without MHD initiating single tablet antiretroviral regimens (STRs) and multi-tablet regimens (MTRs). A retrospective database analysis of the US Medicaid population from Anlitiks’ All Payor Claims database between 1 January 2016 and 30 June 2023 was conducted. Treatment-naïve MTR-initiators vs STR-initiators (the index was the first prescription fill claim date) with ≥ 12-months pre- and post-index continuous enrollment and no pre-index HIV-2 diagnosis among PWH/MHD and PWH/no-MHD during 1 January 2017–30 June 2022 were selected. Demographics, clinical characteristics, HCRU and costs between MTR-initiators vs STR-initiators among PWH/MHD and PWH/no-MHD were described using Chi-square tests and Wilcoxon rank-sum or t-tests for categorical and continuous variables, as appropriate. HCRU and costs were examined using multivariable logistic and gamma-log link regression models, controlling for potential confounders. MTR-initiators (PWH/MHD: n = 7,874, PWH/no-MHD: n = 3,612) vs. STR-initiators (PWH/MHD: 46,024, PWH/no-MHD: 23,452) were significantly younger (PWH/MHD: 43.6 vs. 47.2 years; PWH/no-MHD: 39.2 vs. 43.3 years) and more likely to be female (PWH/MHD: 46.4% vs. 35.7%; PWH/no-MHD: 42.3% vs 29.7%) in both groups (all p-values < 0.05). MTR-initiators vs. STR-initiators had significantly higher rates of inpatient (IP) hospitalizations (PWH/MHD: 28.9% vs. 27.1%; PWH/no-MHD:13.9% vs. 11.9%) and emergency department (ED) visits (PWH/MHD: 53.3% vs. 49.2%; PWH/no-MHD: 35.2% vs. 31.8%) among both those with and without MHD (all p-values < 0.05). MTR-initiators vs. STR-initiators also had significantly higher adjusted all-cause medical costs (PWH/MHD: $60,228 vs $40,634; PWH/no-MHD: $33,623 vs. $17,996) (all p-values < 0.05). Among PWH/MHD and PWH/no-MHD, MTR-initiators experienced significantly higher HCRU, and 1.5 times greater costs compared to STR-initiators. In both MTR and STR-initiator groups, the PWH/MHD cohort consistently demonstrated a greater HCRU and cost burden than the PWH/no-MHD.
Healthcare resource utilization and costs among treatment-naïve people with HIV in state Medicaids: analysis of multi-tablet vs. single-tablet antiretroviral regimen initiators with and without concurrent mental health disorders
Creators: name: Chen, M.
name: Christoph, M.J.
name: Park, S.
name: Turkistani, F.
name: Weinberg, A.R.
name: Trom, C.
name: Zachry, W.
name: Gruber, J.
name: Mordi, U.
name: Rajagopalan, K.
Publisher: name: Taylor & Francis
Year: 2024
Subjects: Medicine
Cancer
Science Policy
Virology

description: Research is needed to understand the impact of mental health disorders (MHD) on healthcare resource utilization (HCRU) and costs among people with human immunodeficiency virus (PWH). Examine the HCRU and cost burden among treatment-naïve PWH with and without MHD initiating single tablet antiretroviral regimens (STRs) and multi-tablet regimens (MTRs). A retrospective database analysis of US Medicaid population from Anlitiks’ All Payor Claims database between 01/01/16 to 06/30/23 was conducted. Treatment-naïve MTR-initiators vs STR-initiators (the index was the first prescription fill claim date) with ≥ 12-months pre- and post-index continuous enrollment and no pre-index HIV-2 diagnosis among PWH/MHD and PWH/no-MHD during 01/01/17-06/30/22 were selected. Demographics, clinical characteristics, HCRU and costs between MTR-initiators vs STR-initiators among PWH/MHD and PWH/no-MHD were described using Chi-square tests and Wilcoxon rank-sum or t-tests for categorical and continuous variables, as appropriate. HCRU and costs were examined using multivariable logistic and gamma-log link regression models, controlling for potential confounders. MTR-initiators (PWH/MHD: n = 7,874, PWH/no-MHD: n = 3,612) vs. STR-initiators (PWH/MHD: 46,024, PWH/no-MHD: 23,452) were significantly younger (PWH/MHD: 43.6 vs. 47.2 years; PWH/no-MHD: 39.2 vs. 43.3 years) and more likely to be female (PWH/MHD: 46.4% vs. 35.7%; PWH/no-MHD: 42.3% vs 29.7%) in both groups (all p-values < 0.05). MTR-initiators vs. STR-initiators had significantly higher rates of inpatient (IP) hospitalizations (PWH/MHD: 28.9% vs. 27.1%; PWH/no-MHD:13.9% vs. 11.9%) and emergency department (ED) visits (PWH/MHD: 53.3% vs. 49.2%; PWH/no-MHD: 35.2% vs. 31.8%) among both those with and without MHD (all p-values < 0.05). MTR-initiators vs. STR-initiators also had significantly higher adjusted all-cause medical costs (PWH/MHD: $60,228 vs $40,634; PWH/no-MHD: $33,623 vs. $17,996) (all p-values < 0.05). Among PWH/MHD and PWH/no-MHD, MTR-initiators experienced significantly higher HCRU, and 1.5 times greater costs compared to STR-initiators. In both MTR and STR-initiator groups, PWH/MHD cohort consistently demonstrated a greater HCRU and cost burden than PWH/no-MHD.
El proyecto extensionista Mariposa para la dignificación de la mujer
Creators: name: Castellanos Machado, Caridad
name: Cebrián Suárez, Daimé
name: Ernesto Paz Enrique, Luis
name: Hernández Alfonso, Eduardo Alejandro
Publisher: name: Humanities Commons
Year: 2020
Subjects: subject: Sustainable development

description: Para las instituciones educativas cubanas la equidad de género y la promoción de las políticas correspondientes son esenciales para el proceso docente - educativo. La emergencia de distintos espacios donde se reconozca a la mujer en cualquiera de las esferas sociales donde se desarrolla ha teniendo en cuenta eliminar estereotipos y patrones de comportamientos heteronormativos heredados de una sociedad patriarcal en la que hombres y mujeres difieren no solo en su anatomía, sino también en su condición social. Aunque Cuba avanza en el desarrollo de procesos de equidad de género, aún quedan vestigios del patriarcado normando diferentes procesos sociales. Por tal motivo, en el área de extensión universitaria se desarrollan espacios y proyectos que se configuran para homenajear a la mujer. Se plantearon como objetivos del estudio: 1) socializar los resultados obtenidos de un proyecto extensionista universitario para resaltar la labor de la mujer y 2) examinar el enfoque teórico y metodológico del Proyecto Mariposa. Mariposa es un proyecto que nace desde el año 2012 para estimular a mujeres consagradas que trabajan o han trabajado en la Universidad Central “Marta Abreu” de Las Villas, Cuba. El proyecto presenta un enfoque humanista y emancipador de la mujer.
Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes
Creators: name: McEwan, Phil
name: Bøg, Martin
name: Faurby, Mads
name: Foos, Volker
name: Lingvay, Ildiko
name: Lübker, Christopher
name: Miller, Ryan
name: Toliver, Joshua C.
name: Yeates, Florian
name: Lincoff, A. Michael
Publisher: name: Taylor & Francis
Year: 2025
Subjects: subject: Medicine
subject: Pharmacology
subject: Sociology
subject: FOS: Sociology
subject: Science Policy

description: The cardioprotective effects of semaglutide 2.4 mg reported in the SELECT cardiovascular (CV) outcomes trial (ClinicalTrials.gov NCT03574597) provide clinical benefit for subjects with overweight or obesity and established CV disease without type 2 diabetes (T2D). We assessed cost-effectiveness of semaglutide 2.4 mg in this population against the American College of Cardiology/American Heart Association value framework. A cohort-level Markov-state cost-effectiveness model using trial-derived data with outcomes from a healthcare sector perspective measured over a lifetime horizon was developed. Treatment costs were based on US list prices; scenario analyses used literature-reported estimated rebates. Healthcare costs and benefits were discounted at 3.0%. A simulated cohort of 100,000 subjects was aligned to the SELECT trial population baseline characteristics and time-on-treatment. Subjects received either semaglutide 2.4 mg or placebo in addition to standard of care (SoC). Modelled outcomes included clinical events (CV events, progression to T2D, chronic kidney disease [CKD]) and health economic measures, including direct costs and quality-adjusted life years (QALYs). Mean semaglutide 2.4 mg treatment duration was 2.79 years. Per 100,000 subjects, treatment avoided 2,791 non-fatal myocardial infarctions, 3,000 coronary revascularizations, 487 non-fatal strokes, and 115 CV deaths over the modeled lifetime horizon. Average per-subject lifetime treatment costs were $47,353; savings arose from avoided T2D ($14,431), CKD ($2,074), and CV events ($1,512). Semaglutide 2.4 mg was associated with increased lifetime costs ($29,767), additional QALYs gained (0.218) and an incremental cost-effectiveness ratio of $136,271/QALY at list price; a scenario using an empirically estimated 48% rebate predicted $32,219/QALY. The generalizability of observations from SELECT to a broader US population is unknown. Our model does not capture all outcomes nor costs that may be affected by weight loss. Modeling assumptions may present limitations. Semaglutide 2.4 mg use as in SELECT is cost-effective at list price, using a $150,000/QALY willingness-to-pay threshold.
The most recent Baltic Sea marine hunter-gatherers? The buried individual of grave IB3 in the Suutarinniemi cemetery, Finland
Creators: name: Hakamäki, Ville
name: Kuusela, Jari-Matti
name: Lahtinen, Maria
Publisher: name: Humanities Commons
Year: 2022
Subjects: subject: Archaeology
subject: Stable isotopes
subject: Middle Ages
subject: Northern Europe

description: Most European hunter-gatherers slowly assimilated into farming communities during the Neolithic period. In the north these groups persisted far longer. In this paper, we present evidence from what may be one of the most recent non-agricultural sites in the region, where a marine hunter-gatherer lifestyle may have continued until as late as the 15th–16th centuries AD. The isotope composition of incremental dental analysis suggests a significant, longterm dependence on seals. This indicates that vestiges of this means of subsistence might have been present in Europe for much longer than previously thought.
The cost-effectiveness of treatment for high-risk, early-stage, triple-negative breast cancer in Egypt: an analysis of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab
Creators: name: Pöllinger, Bernadette
name: Haiderali, Amin
name: Huang, Min
name: Ersoy, Burcu Akyol
name: Abdelaziz, Ahmed H.
name: Kassem, Loay
name: Elsisi, Gihan Hamdy
Publisher: name: Taylor & Francis
Year: 2025
Subjects: subject: Medicine
subject: Pharmacology
subject: Biotechnology
subject: Sociology
subject: FOS: Sociology
subject: Information Systems not elsewhere classified
subject: Developmental Biology
subject: Cancer

description: The cost-effectiveness of neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab compared to neoadjuvant chemotherapy plus placebo followed by adjuvant placebo was assessed in high-risk, early-stage, triple-negative breast cancer patients from an Egyptian societal perspective over a lifetime horizon. A 4-state Markov cohort model was developed to compare the cost-effectiveness of pembrolizumab + chemotherapy/pembrolizumab vs chemotherapy alone for the treatment of high-risk, early-stage, triple-negative breast cancer. The model simulated the clinical course of high-risk, early-stage, triple-negative breast cancer across four health states: event-free survival, locoregional recurrence, distant metastasis, and death. Clinical inputs for the simulation were derived from modeling of efficacy and safety data collected in the KEYNOTE-522 trial. Direct medical costs and indirect costs were reported in 2022 Egyptian pounds (EGP) and converted to US dollars ($). Probabilistic and deterministic sensitivity analyses were conducted to assess the robustness of model results. Compared with chemotherapy alone, pembrolizumab + chemotherapy/pembrolizumab led to expected gains of 2.92 life years and 2.25 quality-adjusted life years, respectively, while increasing overall treatment costs by EGP 491,695 ($102,436). Incremental costs per year gained were EGP 218,285 ($45,476) per quality-adjusted life year and EGP 168,223 ($35,046) per life year, both of which were lower than the 2022 Egyptian cost-effectiveness threshold of EGP 398,439 ($83,008). The findings of sensitivity analyses indicated that the model was robust across a range of inputs and assumptions. In Egypt, pembrolizumab + chemotherapy/pembrolizumab is a cost-effective treatment for high-risk, early-stage, triple-negative breast cancer when considering health-related quality-of-life and years of life gained.
Who's Who of WWII Army Psychiatry (Appendix B)
Creators: name: White, Alice
Publisher: name: unknown
Year: 2017
Subjects: subject: History
subject: Great Britain
subject: Military history
subject: Science

description: This appendix gives a brief summary of the role of some individuals who did work connected with Army psychiatry in Second World War Britain (particularly the development of schemes of officer selection and POW rehabilitation). The data was compiled from biographies, autobiographies, obituaries, census information, letters and articles published in newspapers and journals, archive materials and books.
The cost-effectiveness of treatment for high-risk, early-stage, triple-negative breast cancer in Egypt: an analysis of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab
Creators: name: Pöllinger, Bernadette
name: Haiderali, Amin
name: Huang, Min
name: Ersoy, Burcu Akyol
name: Abdelaziz, Ahmed H
name: Kassem, Loay
name: Elsisi, Gihan Hamdy
Publisher: name: Taylor & Francis
Year: 2024
Subjects: subject: Medicine
subject: Pharmacology
subject: Biotechnology
subject: Sociology
subject: FOS: Sociology
subject: Information Systems not elsewhere classified
subject: Developmental Biology
subject: Cancer

description: The cost-effectiveness of neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab compared to neoadjuvant chemotherapy plus placebo followed by adjuvant placebo was assessed in high-risk, early-stage, triple-negative breast cancer patients from an Egyptian societal perspective over a lifetime horizon. A 4-state Markov cohort model was developed to compare the cost-effectiveness of pembrolizumab + chemotherapy/pembrolizumab vs chemotherapy alone for the treatment of high-risk, early-stage, triple-negative breast cancer. The model simulated the clinical course of high-risk, early-stage, triple-negative breast cancer across 4 health states: event-free survival, locoregional recurrence, distant metastasis, and death. Clinical inputs for the simulation were derived from modeling of efficacy and safety data collected in the KEYNOTE-522 trial. Direct medical costs and indirect costs were reported in 2022 Egyptian pounds [EGP] and converted to US dollars ($). Probabilistic and deterministic sensitivity analyses were conducted to assess the robustness of model results. Compared with chemotherapy alone, pembrolizumab + chemotherapy/pembrolizumab led to expected gains of 2.92 life years and 2.25 quality-adjusted life years, respectively, while increasing overall treatment costs by EGP 491695 [$102436]. Incremental costs per year gained were EGP 218285 [$45476] per quality-adjusted life year and EGP 168223 [$35046] per life year, both of which were lower than the 2022 Egyptian cost-effectiveness threshold of EGP 398439 [$83008]. The findings of sensitivity analyses indicated that the model was robust across a range of inputs and assumptions. In Egypt, pembrolizumab + chemotherapy/pembrolizumab is a cost-effective treatment for high-risk, early-stage, triple-negative breast cancer when considering health-related quality of life and years of life gained.
The role of sodium zirconium cyclosilicate drug utilization in managing hyperkalemia: impact on healthcare resource utilization and on maintenance of renin-angiotensin-aldosterone system inhibitor therapy in Italian clinical practice
Creators: name: Gnesi, Marco
name: Daniel, Francesca
name: Mongelli, Valentina
name: Merlo, Andrea
name: Cosentino, Nicola
name: Maurizi, Anna Rita
name: Nugnes, Marta
name: Leogrande, Melania
name: Degli Esposti, Luca
Publisher: name: Taylor & Francis
Year: 2025
Subjects: Medicine
Pharmacology
Environmental Sciences not elsewhere classified
Biological Sciences not elsewhere classified
Information Systems not elsewhere classified
Science Policy

description: Hyperkalemia (HK) is prevalent in patients with chronic kidney disease (CKD) and heart failure, particularly those on renin-angiotensin-aldosterone system inhibitors (RAASi). However, HK treatment often necessitates RAASi discontinuation. Sodium zirconium cyclosilicate (SZC), reimbursed in Italy since 2021, offers a new treatment option for HK. This study aimed to assess real-world SZC use and resulting economic rebounds in Italy. Using administrative databases of healthcare entities covering about 6 million residents, patients with at least one prescription of SZC from Jan-2022 to Jun-2023 were identified. Patients receiving other potassium binders after SZC initiation were excluded. A logistic regression model estimated odds ratios (OR) with 95% confidence interval (95%CI) for predictors of long-term SZC use (>90 days), including age, sex, CKD status, and comorbidities. Univariate regression identified the potential association between each individual predictor and the likelihood of long-term treatment, followed by multivariate analysis adjusted for confounders. A backward stepwise logistic regression method retained only significant predictors, enhancing model accuracy. The study identified 355 SZC-treated patients (mean age 70.4 years, 64.2% male). CKD was found in 69.3% (47.6% on dialysis), with common comorbidities including hypertension (57.5%), diabetes (43.4%), and heart failure (23.4%). RAASi use was observed in 68.7% before SZC initiation, and RAASi discontinuation was lower in long-term SZC users compared to short-term SZC users (41.2 vs. 56.6%, p = 0.048). Short-term SZC treatment (≤90 days) was more frequent (83.1%) and predicted by dialysis (OR = 0.22). Healthcare costs over 6 months averaged €7,943 for short-term users (dialysis: €3,452) and €6,647 for long-term users (dialysis: €1,130). This real-world study showed that nearly 17% of patients continued SZC therapy for ≥90 days. Long-term therapy was associated with lower RAASi discontinuation and reduced healthcare costs due to hospitalizations and outpatient specialist services, suggesting that SZC can potentially provide clinical and economic benefits for HK management.
Decision model to evaluate the cost of clinical events associated with switching from apixaban to rivaroxaban among patients with non-valvular atrial fibrillation in the United States and Germany
Creators: name: Subash, Rupesh
name: Duan, Cecilia
name: Shah, Anshul
name: Hines, Dionne M.
name: Zhang, Michelle
name: Kongnakorn, Thitima
name: Dworatzek, Elke
name: Kisser, Agnes
name: Hagan, Melissa
Publisher: name: Taylor & Francis
Year: 2025
Subjects: subject: Medicine
subject: Environmental Sciences not elsewhere classified
subject: Sociology
subject: FOS: Sociology
subject: Biological Sciences not elsewhere classified
subject: Science Policy

description: Direct-acting oral anticoagulants (DOACs) have emerged as the preferred treatment for nonvalvular atrial fibrillation (NVAF). However, evidence concerning the economic outcomes of DOAC switching remains limited. This study aimed to assess the economic outcomes of DOAC switching in the US and Germany, two countries with a high AF prevalence and DOAC utilization. A decision model was developed to assess the incidence and cost of stroke/systemic embolism (SE) and major bleeding (MB) associated with switching from apixaban to rivaroxaban in patients with NVAF. The model compared two scenarios: continuers (patients continuing apixaban) and switchers (patients switching from apixaban to rivaroxaban). Model inputs on clinical event rates were sourced from a published real-world study, cost inputs were from a standard costing database and published literature. The analysis was conducted over a 1-year time horizon from US Medicare fee-for-service and German public healthcare payer perspectives. Over one year, 47,036 patients among a hypothetical plan size of 1,000,000 US Medicare fee-for-service members and 1,019,079 patients among the German adult population size of 70,107,122 were estimated to be treated for NVAF with apixaban. Switching all patients from apixaban to rivaroxaban resulted in 1,498 and 32,447 additional clinical events (stroke/SE and MB) and deaths in the US and Germany, respectively, compared to continuing with apixaban. This led to a total incremental cost of $17.3 million and €153 million from Medicare fee-for-service and German public healthcare perspectives, respectively. The incidence and hazard ratios of clinical events informing this analysis were based on a US commercial and Medicare Advantage population and may not be generalizable to other populations. Switching from apixaban to rivaroxaban was associated with increased clinical events, deaths, and higher medical care costs, potentially representing a less favorable strategy economically compared to continuing apixaban among patients with NVAF.
Diseño de la revista científica electrónica “Investigación Multimedia”
Creators: name: Ernesto Paz Enrique, Luis
name: Hernández Alfonso, Eduardo Alejandro
name: Ruíz Herrera, Darianna
Publisher: name: Humanities Commons
Year: 2018
Subjects: subject: Periodicals

description: Las revistas científicas son actualmente el medio principal para socializar los resultados de procesos investigativos. La temática multimedia tiene actualmente una producción científica sostenida a partir de hipertexto y las tecnologías de la información y las comunicaciones. Se plantean como objetivos de este estudio: 1) identificar las necesidades de información de los usuarios potenciales para diseñar una publicación para socializar los estudios multimedia y 2) diseñar una revista científica electrónica para socializar los resultados de investigación de la temática multimedia. Para la obtención de resultados se emplean métodos y técnicas en los niveles teórico y empírico. Se identifican las necesidades de información de los usuarios potenciales para diseñar una publicación científica para socializar los estudios multimedia y se diseña una revista científica electrónica centrada en los usuarios como oferta de información.
title: Технологический процесс механической обработки детали «Крышка сквозная»
title: бакалаврская работа
titleType: Subtitle
Creators: name: Махмутов, Родион Раифович
Publisher: name: Unknown
Year: 2016
Subjects: технологический процесс
операционная наладка
базирование

description: Проанализировано назначение детали “Крышка сквозная” приведено описание конструкции. Сформулированы цели и задачи требующие решения в дипломном проекте. Выбран и обоснован способ получения исходной заготовки, оборудование, режущий и контрольно-измерительный инструмент. Предложен вариант технологического процесса механической обработки детали. Рассчитаны режимы резания и выполнено нормирование технологических работ. Рассчитаны и спроектированы специальные станочные и контрольно-измерительные приспособления.
Centrolene hybrida Ruiz-Carranza & Lynch 1991
Creators: name: Rada, Marco
name: Guayasamin, Juan M.
Publisher: name: Zenodo
Year: 2008
Subjects: Biodiversity
Taxonomy
Animalia
Chordata
Amphibia
Anura
Centrolenidae
Centrolene
Centrolene hybrida

description: Centrolene hybrida Ruiz-Carranza & Lynch
Ruiz-Carranza y Lynch (1991b) registraron esta rana para cinco localidades en el flanco oriental de la Cordillera Oriental en los departamentos de Boyacá, Cundinamarca y Caquetá entre los 1700-2200 m. Una localidad adicional de la especie corresponde a material procedente del departamento de Boyacá, municipio de Garagoa, vereda Cienaga-Balvanera, finca reserva natural privada “El Secreto”, quebrada Las Palmitas, 2100 m., MUJ 2225-26 y 5467.
description: Published as part of Rada, Marco & Guayasamin, Juan M., 2008, Redescripción de Cochranella megista (Rivero, 1985) y ampliación de la distribución de nueve ranas de cristal (Anura: Centrolenidae) en Colombia, pp. 89-101 in Papéis Avulsos de Zoologia (São Paulo) (São Paulo) 48 (12) on page 99, DOI: 10.1590/s0031-10492008001200001, http://zenodo.org/record/13314516
Dimensión de la cultura popular y tradicional como recurso para el desarrollo local
Creators: name: Alcívar Molina, Silvio Alejandro
name: Ernesto Paz Enrique, Luis
name: Martínez Casanova, Manuel
Publisher: name: Humanities Commons
Year: 2020
Subjects: subject: Sustainable development

description: El desarrollo local como proceso histórico concreto tiene un carácter multidisciplinar. La cultura popular y tradicional es una de las dimensiones del desarrollo local que si es potenciada puede revertirse en beneficio de los individuos. Existe en el orden teórico y metodológico una escasez de fuentes de información científico-técnica, que fundamenten el papel de la cultura popular y tradicional para el desarrollo local. Se plantea como objetivo: identificar los nexos teóricos entre el desarrollo local y la cultura popular y tradicional. Se plantean los postulados teóricos presentes entre la cultura popular y tradicional y el desarrollo local. Se enuncian aspectos que contribuirán a fortalecer el desarrollo local desde la cultura popular y tradicional.
Instituciones con mayor capital científico del campo desarrollo comunitario en Latinoamérica
Creators: name: Barroso Suárez, Yaneisy
name: Ernesto Paz Enrique, Luis
name: Hernández Alfonso, Eduardo Alejandro
Publisher: name: Humanities Commons
Year: 2020
Subjects: subject: Bibliometrics

description: El desarrollo comunitario, como perspectiva, representa una gran oportunidad para los países latinoamericanos. La institucionalización del campo científico desarrollo comunitario en América Latina no ha sido estudiado con anterioridad. Se planteó como objetivo identificar las características del desarrollo comunitario como campo científico en Latinoamérica a partir del análisis de instituciones relativas al mismo. El presente estudio clasificó como descriptivo con aporte teórico, además de ser longitudinal-retrospectivo. Para la obtención de resultados se emplearon métodos en los niveles teórico y empírico, fundamentalmente el método bibliométrico. Se obtiene como resultados que la institución más productiva del campo fue la Universidad Autónoma de México, la misma oferta múltiples programas de formación posgraduada sobre el desarrollo local y comunitario. El resto de las instituciones con mayor capital científico fueron la Universidad Nacional de Colombia, la Universidad de Buenos Aires y la Universidad de la Habana. En el campo científico desarrollo comunitario en Latinoamérica, la revista más productiva es Interações, seguida de Estudios y Perspectivas en Turismo y Eure. La revista Interações de la Universidad Católica Don Bosco, Brasil, es la única revista especializada del campo. La Revista EURE es la mejor posicionada en el campo desarrollo comunitario, sin embargo no puede clasificarse como una publicación especializada del mismo. En el campo científico desarrollo comunitario en Latinoamérica no se evidencian amplias relaciones de colaboración entre instituciones, la mayor parte de la colaboración es intranacional.
title: Технологический процесс механической обработки детали «Стакан»
title: бакалаврская работа
titleType: Subtitle
Creators: name: Прокофьев, Даниил Валерьевич
Publisher: name: Unknown
Year: 2016
Subjects: технологический процесс
операционная наладка
базирование

description: В бакалаврской работе разработан технологический процесс на механическую обработку корпуса, изготовленной из стали 45 ГОСТ 1050 - 88.  Дана характеристика конструктивной и технологической особенности детали. Произведен выбор метода получения заготовки, последовательность обработки, технологическое оборудование, обеспечивающие минимальную трудоемкость и себестоимость изготавливаемой детали при достижении заданного качества. Исходя из этого, рассчитаны припуски и режимы резания с нормированием операций для условий серийного производства. Разработана конструкция приспособления для обработки детали. Работа выполнена в полном объеме и соответствует выданному заданию. В данной ВКР спроектирован прогрессирующий технологический процесс изготовления вала, позволяющий эффективно выполнять повышенную годовую программу выпуска стаканов. Это достигается за счет применения прогрессирующей технологической оснастки, режущего инструмента и контрольного измерительного приспособления. При внедрении в производство данной технологии может быть получен существенный эффект.
Oferta de Información, acercamiento a su fundamentación teórica y epistemológica
Creators: name: Ernesto Paz Enrique, Luis
name: Hernández Alfonso, Eduardo Alejandro
name: Tamayo Rueda, Deymis
Publisher: name: Humanities Commons
Year: 2017
Subjects: subject: Information services

description: El término Oferta de Información carece de un cuerpo conceptual y teórico que la fundamente como categoría científica. Se plantearon como objetivos del estudio: 1) fundamentar epistemológicamente la categoría de oferta de información, 2) establecer los elementos que intervienen en el diseño de ofertas de información y 3) establecer una metodología para el diseño de ofertas de información centrado en el usuario / cliente. El estudio clasifica como descriptivo con aporte teórico. Emplea una metodología cualitativa dominante enfocada en develar los componentes teóricos y metodológicos de la categoría Oferta de Información. Para la obtención de resultados se emplearon métodos en los niveles teórico y empírico, fundamentalmente el análisis documental. Las ofertas de información combinan servicios y productos con la finalidad de satisfacer las necesidades de la comunidad usuaria. El diseño de ofertas debe estar centrado en los usuarios y estar en consonancia con sus requerimientos, grado de solicitud o demanda de la oferta, el nivel de satisfacción, solicitudes no resueltas y la valoración de especialistas. Se planteó una metodología para el diseño de ofertas de información que consta de cuatro etapas generales: documentación, diseño, implementación y evaluación.
Games Design As Learning Tool For Science - The Photonics Games Competition Experience
Creators: name: Chiarello, Fabio
Publisher: name: Zenodo
Year: 2017
Subjects: Photonics
Light
Optics
game-based learning
outreach
didactic
Games design
Board Games
Young people
Photonics Games Competition

description: The presentation gives an overview of the photonics games competition for High School students. The goal of the competition is the creation of an original board game having photonics and light as the central theme. This presentation gives insights into the implementation of the photonics games competition and presents the different games developed within this competition, including the winners.
Decision model to evaluate the cost of clinical events associated with switching from Apixaban to Rivaroxaban among patients with non-valvular atrial fibrillation in the United States and Germany
Creators: name: Subash, Rupesh
name: Duan, Cecilia
name: Shah, Anshul
name: Hines, Dionne M.
name: Zhang, Michelle
name: Kongnakorn, Thitima
name: Dworatzek, Elke
name: Kisser, Agnes
name: Hagan, Melissa
Publisher: name: Taylor & Francis
Year: 2025
Subjects: subject: Medicine
subject: Environmental Sciences not elsewhere classified
subject: Sociology
subject: FOS: Sociology
subject: Biological Sciences not elsewhere classified
subject: Science Policy

description: Direct-acting oral anticoagulants (DOACs) have emerged as the preferred treatment for nonvalvular atrial fibrillation (NVAF). However, evidence concerning the economic outcomes of DOAC switching remains limited. This study aimed to assess the economic outcomes of DOAC switching in the US and Germany, two countries with a high AF prevalence and DOAC utilization. A decision model was developed to assess the incidence and cost of stroke/systemic embolism (SE) and major bleeding (MB) associated with switching from apixaban to rivaroxaban in patients with NVAF. The model compared two scenarios: continuers (patients continuing apixaban) and switchers (patients switching from apixaban to rivaroxaban). Model inputs on clinical event rates were sourced from a published real-world study, costs inputs were from a standard costing database and published literature. The analysis was conducted over a 1-year time horizon from US Medicare fee-for-service and German public healthcare payer perspectives. Over one year, 47,036 patients among a hypothetical plan size of 1,000,000 US Medicare fee-for-service members and 1,019,079 patients among the German adult population size of 70,107,122 were estimated to be treated for NVAF with apixaban. Switching all patients from apixaban to rivaroxaban resulted in 1,498 and 32,447 additional clinical events (stroke/SE and MB) and deaths in the US and Germany, respectively, compared to continuing with apixaban. This led to a total incremental cost of $17.3 million and €153 million from Medicare fee-for-service and German public healthcare perspectives, respectively. The incidence and hazard ratios of clinical events informing this analysis were based on a US commercial and Medicare Advantage population and may not be generalizable to other populations. Switching from apixaban to rivaroxaban was associated with increased clinical events, deaths, and higher medical care costs, potentially representing a less favorable strategy economically compared to continuing apixaban among patients with NVAF.
Oferta de Información, acercamiento a su fundamentación teórica y epistemológica
Creators: name: Ernesto Paz Enrique, Luis
name: Hernández Alfonso, Eduardo Alejandro
name: Tamayo Rueda, Deymis
Publisher: name: unknown
Year: 2017
Subjects: subject: Information services

description: El término Oferta de Información carece de un cuerpo conceptual y teórico que la fundamente como categoría científica. Se plantearon como objetivos del estudio: 1) fundamentar epistemológicamente la categoría de oferta de información, 2) establecer los elementos que intervienen en el diseño de ofertas de información y 3) establecer una metodología para el diseño de ofertas de información centrado en el usuario / cliente. El estudio clasifica como descriptivo con aporte teórico. Emplea una metodología cualitativa dominante enfocada en develar los componentes teóricos y metodológicos de la categoría Oferta de Información. Para la obtención de resultados se emplearon métodos en los niveles teórico y empírico, fundamentalmente el análisis documental. Las ofertas de información combinan servicios y productos con la finalidad de satisfacer las necesidades de la comunidad usuaria. El diseño de ofertas debe estar centrado en los usuarios y estar en consonancia con sus requerimientos, grado de solicitud o demanda de la oferta, el nivel de satisfacción, solicitudes no resueltas y la valoración de especialistas. Se planteó una metodología para el diseño de ofertas de información que consta de cuatro etapas generales: documentación, diseño, implementación y evaluación.
Comparing pulsed field ablation and thermal energy catheter ablation for paroxysmal atrial fibrillation: a cost-effectiveness analysis of the ADVENT trial
Creators: name: Padula, William V.
name: Paffrath, Alexandra
name: Jacobsen, Caroline M.
name: Cohen, Benjamin G.
name: Nadboy, Rachel
name: Sutton, Brad S.
name: Gerstenfeld, Edward P.
name: Mansour, Moussa
name: Reddy, Vivek Y.
Publisher: name: Taylor & Francis
Year: 2025
Subjects: subject: Medicine
subject: Microbiology
subject: FOS: Biological sciences
subject: Ecology
subject: Sociology
subject: FOS: Sociology
subject: Biological Sciences not elsewhere classified
subject: Science Policy
subject: Infectious Diseases
subject: FOS: Health sciences

description: Pulsed field ablation (PFA) has emerged as an effective technology in the treatment of paroxysmal atrial fibrillation (AF). To evaluate the cost-effectiveness of PFA vs. thermal ablation from a US healthcare payer perspective using data from a randomized trial. A hybrid decision tree and Markov model was developed comparing patients receiving PFA to thermal ablation (either radiofrequency or cryoballoon ablation) from a US healthcare payer perspective at 5-, 10-, 20-, and 40-year time horizons. Direct medical costs (in 2024 US Dollars), quality-adjusted life years (QALYs), and the net monetary benefit were evaluated at a willingness-to-pay (WTP) threshold of $100,000/QALY. Univariate and probabilistic sensitivity analyses were performed to test model uncertainty. The budget impact for a standard US healthcare payer with 1 million beneficiaries was also assessed. Over a 40-year time horizon, PFA resulted in an additional 0.044 QALYs at a lower cost of $2,871 compared to thermal ablation. PFA was cost-effective in 54.9% of simulations. Anticoagulation and ablation procedure costs had the largest impact on model uncertainty. The expected cost savings per member per month for a US healthcare payer adopting PFA were $0.00015, $0.0059, and $0.02343 in years 1, 4, and 6, respectively. PFA was at least as cost-effective as conventional thermal ablation modalities for treatment of paroxysmal AF and potentially reduces US healthcare payer costs. Providers and payers should consider designating PFA among the preferred first-line therapies for eligible patients.
Centrolene quindianum Ruiz-Carranza & Lynch 1995
Creators: name: Rada, Marco
name: Guayasamin, Juan M.
Publisher: name: Zenodo
Year: 2008
Subjects: Biodiversity
Taxonomy
Animalia
Chordata
Amphibia
Anura
Centrolenidae
Centrolene
Centrolene quindianum

description: Centrolene quindianum Ruiz-Carranza & Lynch
Especie conocida hasta el momento de la localidad tipo (municipio de Finlandia, departamento de Quindío) y dos localidades adicionales en los municipios de Salento y Pereira sobre el flanco occidental de la Cordillera Central, departamentos de Quindío y Risaralda (1900-2050 m; Ruiz-Carranza & Lynch 1995c). Dos nuevos registros de esta especie permiten ampliar el rango de distribución en cerca de 250 km al sur, Departamento del Cauca, municipio de Popayán, vereda La Cabuyera, sitio “El Cofre”, 1700 m (MHNUC 0144) y en cerca de 150 km al norte, departamento de Antioquia, municipio de Caldas, vereda Clara, alto de San Miguel, 1920 m (MHUA 5155-6).
description: Published as part of Rada, Marco & Guayasamin, Juan M., 2008, Redescripción de Cochranella megista (Rivero, 1985) y ampliación de la distribución de nueve ranas de cristal (Anura: Centrolenidae) en Colombia, pp. 89-101 in Papéis Avulsos de Zoologia (São Paulo) (São Paulo) 48 (12) on page 99, DOI: 10.1590/s0031-10492008001200001, http://zenodo.org/record/13314516
sj-pdf-1-asu-10.1177_0003134820950685 - Supplemental material for Electronic Glycemic Management System and Endocrinology Service Improve Value in Cardiac Surgery
Creators: name: Chancellor, William Z.
name: Mehaffey, James H.
name: Hawkins, Robert B.
name: Charles, Eric J.
name: Tribble, Curt
name: Yarboro, Leora T.
name: Gorav Ailawadi
name: Kirby, Jennifer L.
Publisher: name: SAGE Journals
Year: 2021
Subjects: subject: 110323 Surgery
subject: FOS: Clinical medicine

description: Supplemental material, sj-pdf-1-asu-10.1177_0003134820950685, for Electronic Glycemic Management System and Endocrinology Service Improve Value in Cardiac Surgery by William Z. Chancellor, James H. Mehaffey, Robert B. Hawkins, Eric J. Charles, Curt Tribble, Leora T. Yarboro, Gorav Ailawadi and Jennifer L. Kirby in The American Surgeon